Leerink Partnrs Issues Optimistic Forecast for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Leerink Partnrs lifted their FY2024 earnings per share estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($2.00) per share for the year, up from their prior estimate of ($2.05). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q4 2024 earnings at ($0.50) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($2.60) EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Wedbush reissued an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Finally, Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Price Performance

STOK stock opened at $13.27 on Friday. Stoke Therapeutics has a fifty-two week low of $3.77 and a fifty-two week high of $17.58. The stock has a market capitalization of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95. The business’s fifty day moving average price is $13.24 and its two-hundred day moving average price is $13.70.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in STOK. Quest Partners LLC bought a new stake in Stoke Therapeutics in the second quarter worth approximately $29,000. Nisa Investment Advisors LLC increased its holdings in Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Stoke Therapeutics in the second quarter worth approximately $123,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $141,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares in the last quarter.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.